CoChat

Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts

Open access
Axelsen, LN, Keung, W, Pedersen, HD, Meier, E, Riber, D, Kjølbye, AL, Petersen, JS, Proctor, SD, Holstein‐Rathlou, N‐H, Lopaschuk, GD · 2012 · British Journal of Pharmacology
Cited by 31

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE The prevalence of heart disease continues to rise, particularly in subjects with insulin resistance (IR), and improved therapies for these patients is an important challenge. In this study we evaluated cardiac function and energy metabolism in IR JCR:LA‐cp rat hearts before and after treatment with an inotropic compound (glucagon), a glucagon‐like peptide‐1 (GLP‐1) receptor agonist (ZP131) or a glucagon‐GLP‐1 dual‐agonist (ZP2495). EXPERIMENTAL APPROACH Hearts from IR and lean JCR:LA rats were isolated and perfused in the working heart mode for measurement of cardiac function and metabolism before and after addition of vehicle, glucagon, ZP131 or ZP2495. Subsequently, cardiac levels of nucleotides and short‐chain CoA esters were measured by HPLC. KEY RESULTS Hearts from IR rats showed decreased rates of glycolysis and glucose oxidation, plus increased palmitate oxidation rates, although cardiac function and energy state (measured by ATP/AMP ratios) was normal compared with control rats. Glucagon increased glucose oxidation and glycolytic rates in control and IR hearts, but the increase was not enough to avoid AMP and ADP accumulation in IR hearts. ZP131 had no significant metabolic or functional effects in either IR or control hearts. In contrast, ZP2495 increased glucose oxidation and glycolytic rates in IR hearts to a similar extent to that of glucagon but with no concomitant accumulation of AMP or ADP. CONCLUSION AND IMPLICATIONS Whereas glucagon compromised the energetic state of IR hearts, glucagon‐GLP‐1 dual‐agonist ZP2495 appeared to preserve it. Therefore, a glucagon‐GLP‐1 dual‐agonist may be beneficial compared with glucagon alone in the treatment of severe heart failure or cardiogenic shock in subjects with IR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01714.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 31

Metadata

Authors
Axelsen, L., Keung, W., Pedersen, H., Meier, E., Riber, D., Kjølbye, A., Petersen, J., Proctor, S., Holstein‐Rathlou, N., & Lopaschuk, G.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-03-23
Volume
165
Issue
8
Pages
2736-2748
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1588301406
Cited by
31
References
6
FWCI
2.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01714.x
The paper
Axelsen, L., Keung, W., Pedersen, H., Meier, E., Riber, D., Kjølbye, A., Petersen, J., Proctor, S., Holstein‐Rathlou, N., & Lopaschuk, G. (2012). Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01714.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.